维普中文期刊产品整合服务
215篇 您的检索式:作者名="ILK"
    题名 作者 年代 出处 被引量
1极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验显示文摘背景:以前的血管内超声(intravascular ultrasound,IVUS)试验证实,他汀治疗可减缓或阻止动脉粥样硬化的进展,但是迄今尚无应用动脉粥样斑块体积百分比(percent atheroma volume,PAV)证实粥样硬化消退的确切证据。PAV是最严格的评价病变进展和消退的IVUS测量指标。 目标:评价极高强度他汀治疗是否能逆转IVUS确定的冠状动脉粥样硬化。 设计和地点:于美国、加拿大、欧洲和澳大利亚53个社区和3级保健中心进行前瞻性开标盲法终点试验(A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden,ASTEROID)。应用马达驱动回撤IVUS评价基线和治疗24个月时冠状动脉粥样斑块负荷。每对基线和随访IVUS测量结果均进行盲法分析。 病例:从2002年11月到2003年10月,507例患者有基线IVUS检查结果,并接受至少1个剂量的研究药物。在24个月后,349例患者具有可用于评估的系列IVUS检查结果。 干预:所有患者均接受瑞舒伐他汀40ms/d强化治疗。 主要观测指标:预先设定了两个一级疗效指标:PAV变化和基线最严重病变10min节段动脉粥样斑块体积变化。二级疗效指标为整个动脉标准化总斑块体积的变化。结果:平均(SD)LDL—C水平由基线时的130.4(34.3)ms/dL降至60.8(20.0)ms/扎,平均下降了53.2%(P〈0.001)。平均(SD)HDL-C水平从基线时的43.1(11.1)ms/dL升至49.0(12.6)ms/dL,平均增加了14.7%(P〈0.001)。整个血管PAV平均(SD)变化为-0.98%(3.15%),中位数为-0.79%(97.5%CI,-1.21%~-0.53%)(与基线比较,P〈0.001)。最严重病变10min节段斑块体积平均(SD)变化为-6.1(10.1)mm^3,中位数为-5.6mm^3(97.5%CI,-6.8~-4.0mm^3)(与基线比较,P〈0.001)。总斑块体积变化中位数降低了6.8%,平均减少了-14.7(25.7)mm^3,中位数为-12.5mm^3(95%CI,-15.1~-10.5mm^3)(与基线比较,P〈0.001)。不良事件少见,与其他他汀试验相似。 结论:应用瑞舒伐他汀40ms/d进行极高强度他汀治疗可使LDL-C平均水平达到60.8ms/dL,使HDL—C增加14.7%。这导致所有3个预先设定的IVUS斑块负荷指标均显示动脉粥样硬化消退。因此,将LDL-C降至低于目前指南规定的水平,同时显著提高HDL-C,可以使冠心病患者动脉粥样硬化斑块消退。这些变化对临床预后的影响尚需进一步研究确定。Steven E. Nissen Stephen J. Nicholls Ilks Sipahi Peter Libby Joel S. Raichlen Christie M. Ballantyne Jean Davignon Raimund Erbel Jean Charles Fruchart Jean-Claude Tardif Paul Schoenhagen Tim Crowe Valerie Cain Kathy Wolski Marlene Coormastic E. Murat Tuzcu 仝其广(译) 王淑敏(译) 胡大一(校) 2006美国医学会杂志(中文版)2006,25,4:341
2Role of liver biopsy in nonalcoholic fatty liver disease显示文摘Nonalcoholic fatty liver disease(NAFLD), defined as abnormal accumulation(> 5%) of hepatic triglyceride without excess alcohol intake, is the most common form of chronic liver disease in adults and children in the United States. NAFLD encompasses a spectrum of histologic findings including uncomplicated steatosis, steatosis with inflammation and steatohepatitis [nonalcoholic steatohepatitis(NASH)]; the latter can advance to cirrhosis and hepatocellular carcinoma. NASH is currently accepted as the hepatic manifestation of the set of cardiovascular risk factors collectively known as metabolic syndrome. In 1999 a system for histologic grading and staging for NASH was proposed; this was revised by the NASH Clinical Research Network in 2005 for the entire spectrum of lesions in NAFLD, including the lesions and patterns of pediatric NAFLD, and for application in clinical research trials. Diagnosis remains distinct from grade and stage. A recent European proposal separates steatosis from activity to derive a numeric diagnosis of NASH. Even though there have been promising advancements in non-invasive testing, these tests are not yet detailed enough to replace the full range of findings provided by liver biopsy evaluation. Limitations of biopsy are acknowledged, but liver biopsy remains the 'gold standard' for diagnosis and determination of amounts of necroinflammatory activity, and location of fibrosis, as well as remodeling of the parenchyma in NASH. This review focuses on the specific histologic lesions of NAFLD and NASH, grading and staging, differential diagnoses to be considered, and the continuing role of the liver biopsy in this important liver disease.ILKe Nalbantoglu Elizabeth M Brunt 2014World Journal of Gastroenterology2014,20,27:16
3Primary sclerosing cholangitis associated colitis: Characterization of clinical, histologic features, and their associations with liver transplantation显示文摘BACKGROUND Primary sclerosing cholangitis(PSC)associated inflammatory bowel disease(IBD)is a unique form of IBD(PSC-IBD)with distinct clinical and histologic features from ulcerative colitis(UC)and Crohn disease(CD).In patients with PSC and IBD,the severity of the two disease processes may depend on each other.AIM To study the histologic and clinical features of PSC patients with and without IBD.METHODS We assessed specimens from patients with UC(n=28),CD(n=10),PSC and UC(PSC-UC;n=26);PSC and CD(PSC-CD;n=6);and PSC and no IBD(PSC-no IBD;n=4)between years 1999-2013.PSC-IBD patients were matched to IBD patients without PSC by age and colitis duration.Clinical data including age,gender,age at IBD and PSC diagnoses,IBD duration,treatment,follow-up,orthotopic liver transplantation(OLT)were noted.RESULTS PSC-UC patients had more isolated right-sided disease(P=0.03),and less active inflammation in left colon,rectum(P=0.03 and P=0.0006),and overall(P=0.0005)compared to UC.They required less steroids(P=0.01)and fewer colectomies(P=0.03)than UC patients.The PSC-CD patients had more ileitis and less rectal involvement compared to PSC-UC and CD.No PSC-CD patients required OLT compared to 38%of PSC-UC(P=0.1).PSC-IBD(PSC-UC and PSCCD)patients with OLT had severe disease in the left colon and rectum(P=0.04).CONCLUSION PSC-UC represents a distinct form of IBD.The different disease phenotype in PSC-IBD patients with OLT may support liver-gut axis interaction,however warrants clinical attention and further research.John Aranake-Chrisinger Themistocles Dassopoulos Yan Yan ILKe Nalbantoglu 2020World Journal of Gastroenterology2020,26,28:3
4Construction of a functional S-layer fusion protein comprising an immunoglobulin G-binding domain for development of specific adsorbents for extracorporeal blood purification显示文摘Vollenkle C Weigert S Ilk N 2004Appl Environ Microbiol2004,70,3:1
5Expression of human ape- lipoprotein(a) kringles in colon cancer cells suppresses an- giogenesis-dependent tumor growth and peritoneal dissemi- nation 显示文摘Yu IlK Ahn JH Lee H J 2005J Gene Med2005,7,:1
6Thoracic aortic injury:how predictive is mechanism and is chest computed tomography a reliable screening tool? A prospective study of 1561 patients显示文摘Dyer DS Moore EE Ilke DN McIntyre RC Bernstein SM Durham JD. 0,,:1
7Bidding behavior in dynamic auction settings:anempirical analysis of ebay显示文摘Ilke O 2010Electronic Commerce Researchand Applications2010,9,2:1
8Peptide transport 显示文摘Ilk D B A 1981Clin Sci1981,60,:1
9Armeniacae semen extract suppresses lipopolysaccharide-induced expressions of cyclooxygenase Jcorrection of cycloosygenaseJ-2 and inducible nitric oxide synthase in mouse BV2 microglial cells显示文摘Chang IlK Yang HY Lee TH 2005Biol Pharm Bu112005,28,:1
10Eger Ⅱ EI:Minimum alveolar concentrations in man on awakening from methoxyflurane,halothane,ether and flurexene anesthesia:MAC awake显示文摘Stoelting ILK Longnecker DE 1970Anesthesiology1970,33,:1
11Orphanin FQ: a neuropeptide that activates an opioid like G protein - coupled receptor显示文摘Reinseheid ILK Nothacker HP Bourson A 1995Science1995,270,5237:1
12Two cases with pachydermoperiostosis and discussion of tamoxifen citrate treatment for arthralgia显示文摘Ay?enur Okten Ilke Mungan Mukaddes Kalyoncu Zerrin Orbak 2007Clinical Rheumatology2007,,1:1
13The relationship of empowermentand selected person~l~ty characteristics to nurs{ng job satisfaction显示文摘Manojlovich M Spence-Laschinger IlK 2002J Nurs Adm2002,32,:1
14Dysphagia after anterior cervical spine surgery: a prospective study using the swallowing- quality of life questionnaire and analysis of patient comorbidities显示文摘Siska PA Ponnappan ILK Hohl JB 2011Spine2011,36,17:1
15Manual versus target-controlled infusions of propofol显示文摘Breslin DS Mirakhur ILK Reid JE 2004Anaesthesia2004,59,:1
16The cerebrovascular re-sponse to traditional acupuncture after stroke 显示文摘Lee JD Chon JS Jeong IlK 2003Neuroradiolo- gy2003,45,11:1
17The AO/ASIF-Proximal femoral nail(PFN) : a new device for the treatment of unstable proximal femoral fractures显示文摘Simmermacher ILK Bosch Am Vander werken C 1999Injury1999,30,3:1
18Large pontine tubercular abscess treated surgically显示文摘Gurjar IlK Joshua SP Agrawal D 2013Br J Neurosurg2013,27,1:1
19Mitochondrial protein pat- terns correlating with impaired insulin secretion from INS-1E cells exposed to elevated glucose concentrations 显示文摘Nyblom IlK Thorn K Ahmed M 2006Proteomics2006,6,19:1
20Antibiotic prescribing pattern in paediatric in patients with frist time wheezing显示文摘PATRA S SINGH V PEMDE IlK 2011Ital J Pediator2011,,37:1
返回顶部 每页显示:
共11页 首页 上一页 第1页 下一页 末页 /11 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费